No Handouts for Drug Advertisements Act

HR 3010, the "No Handouts for Drug Advertisements Act," prohibits pharmaceutical companies from deducting the costs of direct-to-consumer advertising for prescription drugs from their federal taxable income. Specifically, it amends the Internal Revenue Code to disallow tax deductions for advertising expenses related to covered drugs (prescription drugs and certain compounded drugs) when targeted directly at the general public through TV, radio, digital platforms, or billboards. This policy change directly affects pharmaceutical companies that run such advertising campaigns, requiring them to pay taxes on the full cost of these promotions. The bill does not apply to ads in medical journals or other professional publications. It takes effect for expenses incurred after enactment.